EMG
CRL icon

Ellington Management Group’s Charles River Laboratories CRL Stock Holding History

Ellington Management Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-3,500
Closed -$497K – 622
2019
Q2 		$497K Buy
+3,500
New +$475K 0.08% 236
2018
Q1 		– Sell
-9,500
Closed -$1.04M – 847
2017
Q4 		$1.04M Buy
+9,500
New +$1.03M 0.17% 83
2017
Q2 		– Sell
-4,200
Closed -$378K – 688
2017
Q1 		$378K Buy
+4,200
New +$357K 0.01% 396

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Ellington Management Group's CRL Position: Q3 2019 in Review

Ellington Management Group sold out of Charles River Laboratories (CRL) in Q3 2019, closing a stake of 3,500 shares — an estimated $497K sold.

Ellington Management Group first reported a position in CRL in Q1 2017 and held it in 3 quarters. The position peaked at $1.04M in Q4 2017. 396 funds tracked by Wall St. Rank hold CRL as of Q3 2019.

  • Ellington Management Group reported no remaining Charles River Laboratories position as of Q3 2019 after selling out during the quarter.
  • Ellington Management Group sold 3,500 Charles River Laboratories shares in Q3 2019, an estimated $497K.
  • Ellington Management Group first reported a position in Charles River Laboratories in Q1 2017 and held it in 3 quarters.
  • Ellington Management Group's Charles River Laboratories position peaked at $1.04M in Q4 2017.
  • 396 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2019.

Based on Ellington Management Group's 13F filing for Q3 2019, filed 14 Nov 2019.